

## Additions and Corrections

---

1998, Volume 41

**Huseyin Ucar,\* Kim Van derpoorten, Silvia Cacciaguerra, Santi Spampinato, James P. Stables, Paul Depovere, Majed Isa, Bernard Masereel, Jacques Delarge, and Jacques H. Poupaert:** Synthesis and Anticonvulsant Activity of 2(3*H*)-Benzoxazolone and 2(3*H*)-Benzothiazolone Derivatives.

Page 1144. The last sentence of footnote *a* of Table 5 should read as follows:  $\sigma_2$  Binding assays were determined in guinea pig brain using [<sup>3</sup>H]DTG in the presence of an excess of (+)-NANM to mask  $\sigma_1$  binding sites.

JM980259G

S0022-2623(98)00259-3

Published on Web 07/09/1998

**John M. Janusz,\* Patricia A. Young, Michael W. Scherz, Kevin Enzweiler, Laurence I. Wu, Lixian Gan, Stanislaw Pikul, Kelly L. McDow-Dunham, Carl R. Johnson, C. B. Senanayake, David E. Kellstein, Shelley A. Green, Jennifer L. Tulich, Theresa Rosario-Jansen, I. Jack Magrisso, Kenneth R. Wehmeyer, Deborah L. Kuhlbeck, Thomas H. Eichhold, and Roy L. M. Dobson:** New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 2. 7-*tert*-Butyl-2,3-dihydro-3,3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Antiinflammatory and Analgesic Agents: Variations of the Dihydrobenzofuran Ring.

Pages 1124–1137. The compound numbers for structures **2** and **3** (Chart 1) should be switched in Tables 1 and 2 and in the text (except for the Introduction).

Page 1126. In Scheme 4 for the conversion of 2-*tert*-butylaniline to compound **28**, the first reaction on the arrow was omitted and should read as follows: 1. C<sub>6</sub>H<sub>5</sub>CHO, NaBH<sub>3</sub>CN.

Page 1127. The final sentence in the first column should read "... the bioavailability of **3** was quite good ..."

JM980341B

S0022-2623(98)00341-0

Published on Web 07/03/1998